Exagen Inc(XGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.81 | Insider Own | 40.57% | Shs Outstand | 24.2M | Perf Week | 6.6% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | 23.68% | Insider Trans | -0.41% | Shs Float | 14.4M | Perf Month | 1.2% |
| Enterprise Value | 0.21B | PEG | - | EPS next Q | -0.18 | Inst Own | 36.54% | Short Float | 4.68% | Perf Quarter | 79.87% |
| Income | -0.02B | P/S | 2.86 | EPS this Y | 29.71% | Inst Trans | -11.68% | Short Ratio | 1.88 | Perf Half Y | 204.35% |
| Sales | 0.07B | P/B | 16.64 | EPS next 5Y | 28.97% | ROA | -34.19% | Short Interest | 0.67M | Perf YTD | 38.16% |
| Book/sh | 0.5 | P/C | 8.28 | EPS past 3/5Y | 30.65% 6.84% | ROE | -113.82% | 52W High | -29.88% ($11.98) | Perf Year | -29.35% |
| Cash/sh | 1.02 | P/FCF | - | Sales past 3/5Y | 13.47% 9.66% | ROIC | -50.75% | 52W Low | 224.32% ($2.59) | Perf 3Y | 456.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 9.7% | Gross Margin | 58.64% | Volatility(W/M) | 6.96% 6.96% | Perf 5Y | -29.71% |
| Dividend TTM | - | EV/Sales | 2.9 | Sales Y/Y TTM | 20.83% | Oper. Margin | -18.58% | ATR (14) | 0.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.88 | EPS Q/Q | 37.15% | Profit Margin | -26.61% | RSI (14) | 57.1 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.18 | Sales Q/Q | 15.92% | SMA20 | 4.9% ($8.01) | Beta | 2.27 | Target Price | $10.57 |
| Payout | - | Debt/Eq | 2.26 | Earnings | 2026/11/10 | SMA50 | 6.6% ($7.88) | Rel Volume | 0.97 | Prev Close | $7.78 |
| Employees | 216 | LT Debt/Eq | 2.05 | EPS/Sales Surpr. | 32.08% 12.03% | SMA200 | 68.31% ($4.99) | Avg Volume(3M) | 0.36M | Price | $8.4 |
| IPO | 2019/9/19 | Option/Short | Yes/Yes | Trades | 2568 | Volume | 348,278 | Change | 7.97% |
🧬 Exagen is a U.S. life sciences company specializing in diagnostic testing for autoimmune rheumatic diseases. The company supplies its AVISE brand test portfolio to healthcare providers to help them identify and manage complex immune conditions at an early stage—including systemic lupus erythematosus—and focuses on precision testing services that span diagnosis, prognosis, and monitoring.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
Traded about as much as usual. That is 97% of its average volume.
Next earnings report: November 10
12 days to go.
XGN has a sound balance sheet but weak earning power
Of every $100 in sales, $18.58 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +29.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $286. Peers typically go for $458.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -29.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 36.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #34 of 44 in the industry
Based on market cap of $203M.
FAQ
What kind of company is XGN?
XGN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of XGN?
The market cap of XGN is approximately $203M, ranking 4,014 within its sector.
What is the 52-week high and low for XGN?
XGN has recorded a 52-week high of $11.98 and a low of $2.59.
